Compare HUYA & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUYA | SDGR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.0M | 925.8M |
| IPO Year | 2018 | 2020 |
| Metric | HUYA | SDGR |
|---|---|---|
| Price | $3.22 | $12.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $3.50 | ★ $21.00 |
| AVG Volume (30 Days) | 605.0K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 81.37% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $14.08 | $0.76 |
| Revenue Next Year | $6.11 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $2.21 | $10.95 |
| 52 Week High | $4.93 | $27.63 |
| Indicator | HUYA | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 59.52 |
| Support Level | $3.10 | $11.08 |
| Resistance Level | $3.36 | $13.33 |
| Average True Range (ATR) | 0.10 | 0.74 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 58.21 | 81.89 |
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.